178.56
Real-Time Quote
 -1.14 / -0.63%
Today’s Change
88.34
Today|||52-Week Range
181.94
+60.75%
Year-to-Date
Today's Stocks Driving Success For The Drugs Industry
Sep 29 / TheStreet.com
Morning Market Movers
Sep 23 / Benzinga
5 Rocket Stocks to Buy to Avoid the Selloff
Sep 29 / TheStreet.com
Benzinga's Top #PreMarket Gainers
Sep 23 / Benzinga
UPDATE: Allergan Board Offers Statement, Says Valeant's Bid 'Grossly Inadequate'
Sep 29 / Benzinga
Frontrunning: September 23
Sep 23 / Investing Channel
Frontrunning: September 29
Sep 29 / Investing Channel
#PreMarket Primer: Tuesday, September 23: First Airstrikes In Syria Begin
Sep 23 / Benzinga
Allergan Writes Back, Coaxes Shareholders Against Valeant - Analyst Blog
Sep 26 / Zacks.com
US Stock Futures Fall Ahead Of Economic Data
Sep 23 / Benzinga
Why Allergan (AGN) Stock Is Declining in After-Hours Trading Today
Sep 26 / TheStreet.com
Stock Market Today: Traders Gear Up for Volatility Spike
Sep 23 / TheStreet.com
Billionaire Bill Ackmanbs Concentrated Stock Portfolio
Sep 26 / Investing Channel
September 23 Premarket Briefing: 10 Things You Should Know
Sep 23 / TheStreet.com
Valeant (VRX) Sends Letter to Allergan, Provides Q3 Update - Analyst Blog
Sep 25 / Zacks.com
Stocks To Watch For September 23, 2014
Sep 23 / Benzinga
Valeant/Allergan: stand by me
Sep 25 / FT.com
Novo Nordisk Reveals Fresh Data on Xultophy for Diabetes - Analyst Blog
Sep 22 / Zacks.com
Allergan (AGN) Hits New Lifetime High Today
Sep 25 / TheStreet.com
Novartis' (NVS) Data on Anti-Cancer Drug LBH589 Published - Analyst Blog
Sep 22 / Zacks.com
Benzinga's M&A Chatter for Wednesday September 24, 2014
Sep 24 / Benzinga
Bayer to Shed MaterialScience Business, Shares Rise - Analyst Blog
Sep 19 / Zacks.com
Allergan and Salix Pharmaceuticals Up on Takeover Rumors - Analyst Blog
Sep 24 / Zacks.com
Eli Lilly's Trulicity Approved by FDA for Type II Diabetes - Analyst Blog
Sep 19 / Zacks.com
Company News for September 24, 2014 - Corporate Summary
Sep 24 / Zacks.com
Bayer/Orion Progress with Prostate Cancer Drug ODM-201 - Analyst Blog
Sep 18 / Zacks.com
#PreMarket Primer: Wednesday, September 24: US Economy Looking Strong In The Third Qu...
Sep 24 / Benzinga
Merck Enters into Licensing Agreement with Sun Pharma - Analyst Blog
Sep 18 / Zacks.com
Frontrunning: September 24
Sep 24 / Investing Channel
Gilead Down on Weak Simtuzumab Data and Sovaldi News - Analyst Blog
Sep 18 / Zacks.com
Jim Cramer's Top Stock Picks: MWE AGN AAPL AZO
Sep 24 / TheStreet.com
Shire's Vyvanse Accepted for FDA Review for Binge Eating - Analyst Blog
Sep 17 / Zacks.com
Benzinga's M&A Chatter for Tuesday September 23, 2014
Sep 23 / Benzinga
Novo Nordisk's Tresiba Effective in Children & Adolescents - Analyst Blog
Sep 17 / Zacks.com
Dow Down 0.6%; CarMax Shares Fall After Q2 Results
Sep 23 / Benzinga
Abbott Labs (ABT) to Initiate New Trial on Absorb - Analyst Blog
Sep 17 / Zacks.com
Ascena Retail Drops On Downbeat Earnings; CF Industries Shares Gain
Sep 23 / Benzinga
Endo Looking to Acquire Auxilium Pharmaceuticals for $2.2B - Analyst Blog
Sep 17 / Zacks.com
Today's Stocks Driving Success For The Drugs Industry
Sep 23 / TheStreet.com
Roche Starts Trials on Lampalizumab for Geographic Atrophy - Analyst Blog
Sep 16 / Zacks.com
Markets Mixed; Carnival Profit Tops Street View
Sep 23 / Benzinga
AstraZeneca and Eli Lilly Collaborate for Alzheimer's Drug - Analyst Blog
Sep 16 / Zacks.com
Triple A's: Three Stocks to Consider
Sep 23 / TheStreet.com
Gilead (GILD) Slips on Generic Sovaldi Licensing Deals - Analyst Blog
Sep 16 / Zacks.com
Benzinga's Volume Movers
Sep 23 / Benzinga
Avanir Pharmaceuticals Shoots Up on Positive AVP-923 Data - Analyst Blog
Sep 16 / Zacks.com
Stocks Hitting 52-Week Highs
Sep 23 / Benzinga
Bill Ackman plans $2bn Pershing fund IPO in Amsterdam
Sep 15 / FT.com

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.